Abstract Chronic Lymphocytic Leukemia (CLL) is a malignancy of mature B lymphocytes
which are highly dependent on interactions with the tissue microenvironment for their …

Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …

During the past 5 years, a number of highly active novel agents, including kinase inhibitors
targeting BTK or PI3Kδ, an antagonist of the antiapoptotic protein BCL-2, and new anti …

Evolutionarily conserved receptor tyrosine kinase–like orphan receptor-1 and-2 (ROR1/2)
are considered distinct receptors for Wnt5a and are implicated in noncanonical Wnt …

Purpose Few treatment options exist for adult T-cell leukemia/lymphoma (ATL), and the
prognosis for this disease is poor. A phase I study of lenalidomide demonstrated preliminary …

Immune checkpoint blockade antibodies and immunomodulatory drugs can unleash anti-
tumor T cell immunity and mediate durable cancer regressions. However, only a fraction of …

Accumulating evidence suggests that the tumor microenvironment (TME) is involved in
disease progression and drug resistance in B cell malignancies, by supporting tumor growth …

IKAROS is a master regulator of cell fate determination in lymphoid and other hematopoietic
cells. This transcription factor orchestrates the association of epigenetic regulators with …

Highlights•IMID's molecular mechanism explain their efficacy in hematological
malignancies.•Lenalidomide-treated patients become resistant through cancer-specific …

Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and
progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical …